The Role of Finerenone in the Management of Diabetic Nephropathy

被引：0
作者：
Stavroula Veneti
Konstantinos Tziomalos
机构：
[1] Aristotle University of Thessaloniki,First Propedeutic Department of Internal Medicine, Medical School
[2] AHEPA Hospital,undefined
来源：
Diabetes Therapy | 2021年 / 12卷
关键词：
Albuminuria; Diabetic kidney disease; Diabetic nephropathy; Finerenone; Mineralocorticoid receptor antagonists; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Diabetic nephropathy (DN) is the leading cause of chronic kidney disease. Even though mineralocorticoid receptor antagonists (MRA) induce incremental reductions in urine albumin excretion when added to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, this combination is infrequently used because of an increased risk of hyperkalemia. In this context, finerenone, a novel selective MRA that appears to be associated with lower risk for hyperkalemia compared with other MRAs (spironolactone and eplerenone), might represent a useful tool in patients with DN. A recent large randomized trial suggested that finerenone delays the progression of DN and might also reduce cardiovascular morbidity in patients with DN. However, more data are needed to clarify the safety and efficacy of finerenone in this high-risk population.
引用
收藏
页码：1791 / 1797
页数：6
相关论文
共 113 条
  • [1] Oltean S(2017)Diabetic nephropathy: novel molecular mechanisms and therapeutic avenues Biomed Res Int 2017 3146524-271
  • [2] Coward R(2013)Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update Vasc Pharmacol 58 259-1039
  • [3] Collino M(2017)Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment J Am Soc Nephrol 28 1023-272
  • [4] Baelde H(2014)Natural history and clinical characteristics of CKD in type 1 and type 2 diabetes mellitus Adv Chronic Kidney Dis 21 267-2045
  • [5] Arora MK(2017)Diabetic kidney disease: challenges, progress, and possibilities Clin J Am Soc Nephrol 12 2032-37
  • [6] Singh UK(2018)Prognosis and treatment of diabetic nephropathy: recent advances and perspectives Nephrol Ther 14 31-S167
  • [7] Tonneijck L(2021)11. Microvascular complications and foot care: standards of medical care in diabetes—2021 Diabetes Care 44 S151-31
  • [8] Muskiet MHA(2020)Pathophysiologic mechanisms in diabetic kidney disease: a focus on current and future therapeutic targets Diabetes Obes Metab 22 16-161
  • [9] Smits MM(2020)Mineralocorticoid receptor antagonists: a comprehensive review of finerenone Curr Cardiol Rep 22 140-1555
  • [10] Marshall SM(2021)Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine Eur Heart J 42 152-184
12345678910